In the review period, Mark Gan handled financings and dispute resolutions with tight timelines and complex stakeholder demands. Highlights include representing SPV holding renowned Chinese Sci-fi IP in a series of re-arbitration applications, acting in series of litigation over significant dispute between leading MCN company and top KOL, and advising on STR Laser's Series B equity financing exceeding RMB 100 million, Methunutrition’s Series B equity financing exceeding RMB 100 million and Qi-Biodesign's Series A equity financing exceeding RMB 200 million.

For STR Laser, his team joined while prior restructuring was still open and no transactions had closed; they reviewed historical deals, re-sequenced pre-closing steps, drafted a closing timetable, negotiated structure and definitive documents under an accelerated schedule, executed by end-2024, and then assisted through post-signing, closing and follow-ons—achieving more favorable terms than earlier documents.

For Methunutrition, they balanced multi-investor requirements and local government-backed capital constraints, demonstrating the critical role of legal counsel in enabling complex transactions and safeguarding long-term business objectives. He led the Suzhou Qi-Biodesign's Series A financing (by a Beijing municipal investment guidance fund, and existing shareholder), proposing constructive solutions to time-critical investor demands and balancing interests in special terms. Professionally, he broadened his practice by building dispute-resolution capability alongside VC/PE, M&A/restructuring and syndicated lending; emphasized risk prevention in complex structures; and strengthened team leadership and synergy with a focus on stable revenue and resilience. His vision stresses an open, collaborative ecosystem, technology-driven upgrades and deep embedding of legal capability in innovation-economy scenarios, together with cross-border execution frameworks for financing and multinational work.